A detailed history of Emc Capital Management transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Emc Capital Management holds 14,761 shares of CPRX stock, worth $337,584. This represents 0.17% of its overall portfolio holdings.

Number of Shares
14,761
Previous 2,421 509.71%
Holding current value
$337,584
Previous $103,000 199.03%
% of portfolio
0.17%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 23, 2025

BUY
$19.73 - $23.93 $243,468 - $295,296
12,340 Added 509.71%
14,761 $308,000
Q3 2024

Oct 28, 2024

SELL
$15.19 - $21.35 $187,444 - $263,459
-12,340 Reduced 83.6%
2,421 $103,000
Q1 2024

May 20, 2024

SELL
$13.18 - $17.11 $180,855 - $234,783
-13,722 Reduced 48.18%
14,761 $235,000
Q2 2022

Aug 12, 2022

SELL
$6.23 - $8.57 $134,941 - $185,626
-21,660 Reduced 43.2%
28,483 $200,000
Q1 2022

May 16, 2022

BUY
$5.31 - $8.31 $266,259 - $416,688
50,143 New
50,143 $382,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.35B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Emc Capital Management Portfolio

Follow Emc Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emc Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Emc Capital Management with notifications on news.